FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2951-2961

  Dai, Bingbing ^a   Pieper, Russell O ^b   Li, Dawei ^a   Wei, Ping ^a   Liu, Mingguang ^a   Woo, Shiao Y ^a   Aldape, Kenneth D ^a   Sawaya, Raymond ^a   Xie, Keping ^a   Huang, Suyun ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN E; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1B; UBIQUITIN PROTEIN LIGASE NEDD4; UBIQUITIN PROTEIN LIGASE NEDD4 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL TRANSFORMATION; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ASTROCYTES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; CYCLIN E; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; ENZYME ACTIVATION; FORKHEAD TRANSCRIPTION FACTORS; GLIOMA; HUMANS; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; ONCOGENE PROTEIN V-AKT; PHENOTYPE; PTEN PHOSPHOHYDROLASE; UBIQUITIN-PROTEIN LIGASES;

EID: 77950844373     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3909     Document Type: Article

References (49)

1. American Cancer Society. Cancer Facts and Figures 2009; http://www.cancer.org
2. Surawicz TS, Davis F, Freels S, Laws ER, Jr., Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 1998;40:151-160
3. Maher EA, Fumari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-1333
4. Uhrbom L, Kastemar M, Johansson FK, Westermark B, Holland EC Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res 2005;65:2065-2069
5. Bachoo RM, Maher EA, Ligon KL, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002;1:269-277
6. Westermark B, Heldin CH, Nistér M. Platelet-derived growth factor in human glioma. Glia 1995;15:257-263
7. Rasheed BK, Stenzel TT, McLendon RE, et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 1997;57:4187-4190
8. Ermoian RP, Furniss CS, Lamborn KR, et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 2002;8:1100-1106
9. Maier D, Zhang Z, Taylor E, et al. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 1998;16:3331-3335
10. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068
11. Wiencke JK, Zheng S, Jelluma N, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol 2007;9:271-279
12. Wang X, Trotman LC, Koppie T, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007;128:129-139
13. Ye H, Kelly TF, Samadani U, et al. Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol Cell Biol 1997;17: 1626-1641
14. Laoukili J, Kooistra MR, Brás A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005;7:126-136
15. Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007;388:1257-1274
16. Park HJ, Carr JR, Wang Z, et al. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 2009;28:2908-2918
17. Petrovic V, Costa RH, Lau LF, Raychaudhuri P, Tyner AL. FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin (KIS) to promote cell cycle progression. J Biol Chem 2008;283:453-460
18. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 2002;62:4773-4780
19. Madureira PA, Varshochi R, Constantinidou D, et al. The Forkhead box M1 protein regulates the transcription of the estrogen receptor a in breast cancer cells. J Biol Chem 2006;281:25167-25176
20. Kalinichenko W, Major ML, Wang X, et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004;18:830-850 (Pubitemid 38480894)
21. Kalin TV, Wang IC, Ackerson TJ, et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 2006;66:1712-1720
22. Kim IM, Ackerson T, Ramakrishna S, et al. The Forkhead Box ml transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 2006;66:2153-2161
23. Wang IC, Meliton L, Tretiakova M, Costa RH, Kalinichenko VV, Kalin TV. Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene 2008;27: 4137-4149 (Pubitemid 351969912)
24. Yoshida Y, Wang IC, Yoder HM, Davidson NO, Costa RH. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 2007;132:1420-1431
25. Liu M, Dai B, Kang SH, et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 2006;66:3593-3602
26. van den Boom J, Wolter M, Kuick R, et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 2003;163:1033-1043
27. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001 ;61:6885-6891
28. Hodgson JG, Yeh RF, Ray A, et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma tumors and xenografts. Neuro Oncol 2009;11:477-487
29. Dai B, Kang S-H, Gong W, et al. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 2007;26:6212-6219
30. Zhang Y, Zhang N, Dai B, et al. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res 2008;68:8733-8742
31. Sonoda Y, Ozawa T, Hirose Y, et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 2001;61:4956-4960
32. Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Res 2001;61:3556-3560 (Pubitemid 32694959)
33. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 2001;61:6674-6678
34. Holland EC, Celestino J, Dai C, et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000;25:55-57
35. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003;63:2742-2746
36. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 1998;273:13375-13378
37. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
38. Alvarez B, Garrido E, Garcia-Sanz JA, Carrera AC Phosphoinositide 3-kinase activation regulates cell division time by coordinated control of cell mass and cell cycle progression rate. J Biol Chem 2003;278: 26466-26473
39. Asanuma H, Torigoe T, Kamiguchi K, et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005;65:11018-11025
40. Zheng H, Ying H, Yan H, et al p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008; 455:1129-1133
41. Read RD, Cavenee WK, Furnari FB, Thomas JB. A Drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet 2009;5:e1000374.
42. Furnari FB, Lin H, Huang HS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A 1997;94:12479-12484 (Pubitemid 27492554)
43. Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH, Baker SJ. Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 2004;64:7773-7779 (Pubitemid 39446909)
44. Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 2002;1:157-168 (Pubitemid 41039162)
45. Kwon CH, Zhao D, Chen J, et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 2008;68:3286-3294
46. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001;276:993-998 (Pubitemid 32096519)
47. Yim EK, Peng G, Dai H, et al. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009;15: 304-314
48. Chakravarti A, Delaney MA, Noll E, et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001;7:2387-2395 (Pubitemid 32751640)
49. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20:1063-1068 (Pubitemid 34141851)